Unlocking herpes zoster vaccination value in Finland: return on investment and actuarial model.

Authors

Eleftherios Zarkadoulas, Hanna Raunio, Vivi Mauno, Maarten Postma, Nikolaos Kotsopoulos

Published in

The European journal of health economics : HEPAC : health economics in prevention and care. Jul 13, 2026. Epub Jul 13, 2026.

Abstract

Herpes zoster (HZ) is common in Finland, leading to long-term postherpetic neuralgia (PHN) especially with ageing. HZ reduces productivity, placing an economic burden on society. An integrated actuarial and macroeconomic model assessed the return on investment of recombinant zoster vaccine (RZV) in Finland for adults ≥ 50 years versus no vaccination.
A validated economic model determined HZ cases and complications avoided, health gains (quality-adjusted life-years, QALYs), and healthcare cost-savings. Actuarial techniques projected population trends incorporating employment factors. Lost productivity averted through vaccination provided fiscal revenue for the government, and increased gross domestic product (GDP) for society. QALY gains were monetised using 1-3xGDP per QALY. RZV was administered for 20 years, with lifetime impact assessment.
RZV vaccination of around 790,000 50year-olds was estimated to save 3,779 QALYs and €52 million (M) in healthcare costs. Averted productivity losses generated €152 M in fiscal revenue and €367 M in GDP, while vaccination costs were €236 M. From the fiscal perspective, 90% of vaccination costs were offset by fiscal and healthcare cost savings (without considering QALY gains). From the societal perspective, for every €1 invested in vaccination, €2.60-4.10 was saved (depending on QALY value). The benefit-cost ratio (BCR) remained positive across sensitivity analyses. The highest BCRs were achieved when vaccinating adults aged 50 years; or 65 years when excluding productivity benefits.
RZV vaccination in working-age adults yielded economic benefits in Finland, generating €2.60-4.10 for society per €1 invested in vaccination, and with fiscal benefits offsetting 90% of vaccination costs.

PMID:
42440058
Bibliographic data and abstract were imported from PubMed on 13 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.